Metabolomic changes in autopsy-confirmed Alzheimer's disease

Alzheimer's and Dementia

Volumn 7, Issue 3, 2011, Pages 309-317

  Kaddurah Daouk, Rima ^a   Rozen, Steve ^a,b   Matson, Wayne ^c   Han, Xianlin ^d   Hulette, Christine M ^e   Burke, James R ^e   Doraiswamy, P Murali ^a   Welsh Bohmer, Kathleen A ^a,e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's; Biomarkers; Diagnosis; Metabolomics; Purine; Staging; Tryptophan; Tyrosine

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ALPHA TOCOPHEROL; ASCORBIC ACID; CYSTINE; DOPAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GUANOSINE; HOMOVANILLIC ACID; HYPOXANTHINE; INDOLEACETIC ACID; KYNURENINE; LEVODOPA; METHIONINE; N ACETYLSEROTONIN; NORADRENALIN; PHENYLALANINE; PURINE; SEROTONIN; SULFUR AMINO ACID; TOCOPHEROL; TRYPTOPHAN; TYRAMINE; TYROSINE; URIC ACID; VANILMANDELIC ACID; XANTHINE; XANTHOSINE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN METABOLISM; BRAIN VENTRICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; COULOMETRY; ELECTROCHEMISTRY; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METABOLITE; METABOLOMICS; OXIDATIVE STRESS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUTOPSY; BIOGENIC AMINES; BIOLOGICAL MARKERS; ELECTROCHEMICAL TECHNIQUES; FEMALE; HUMANS; MALE; METABOLOMICS; OXIDATIVE STRESS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PURINES; TOCOPHEROLS;

EID: 79956130559     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2010.06.001     Document Type: Article

References (41)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 2009;5:3.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
4. Lopponen M, Raiha I, Isoaho R, Vahlberg T, Kivela SL. Diagnosing cognitive impairment and dementia in primary health care - a more active approach is needed. Age Ageing 2003;32:606-12. (Pubitemid 37461568)
5. Hyman BT, Trojanowski JQ. Consensus recommendations for the post-mortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-7.
6. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000;15:93-101. (Pubitemid 30340226)
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. (Pubitemid 34790756)
8. Albers DS, Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 2000;59:133-54. (Pubitemid 30479414)
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-13.
10. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 2006;358:159-74.
11. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. Metabolomics in the study of aging and caloric restriction. Methods Mol Biol 2007;371:393-409. (Pubitemid 350183437)
12. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008;48:653-83. (Pubitemid 351738167)
13. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system disease. Neuropsychopharmacology 2009;34:173-86.
14. Kell DB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol 2004;7:296-307. (Pubitemid 38765114)
15. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005;1:101-8. (Pubitemid 40778831)
16. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001;77:1168-80. (Pubitemid 32467071)
17. Greenberg N, Grassano A, Thambisetty M, Lovestsone S, Legido- Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 2009;30:1235-9.
18. Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S, et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 2005;77:4108-16. (Pubitemid 40934277)
19. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 2006;522:418-23.
20. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007;12:934-45. (Pubitemid 47482696)
21. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389-96.
22. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2009;28:1-16.
23. Patkar AA, Rozen S, Mannelli P, Matson W, Pae CU, Krishnan RR, et al. Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. Psychopharmacology (Berl) 2009;206:479-89.
24. Mannelli P, Patkar A, Rozen S, Matson W, Krishnan R, Kaddurah- Daouk R. Opioid use affects antioxidant activity and purine metabolism: preliminary results. Hum Psychopharmacol 2009;24:666-75.
25. Hulette CM, Welsh-Bohmer KA, Crain B, Szymanski MH, Sinclaire NO, Roses AD. Rapid brain autopsy: the Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med 1997;121:615-8.
26. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
27. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's Disease (CERAD) Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-86.
28. Storey JD, Tibshirani R. Statistical significance for genome-wide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
29. Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent, technical report. Available at: http://www-stat.stanford.edu/wjhf/ftp/glmnet.pdf 2008.
30. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. New York, NY: Springer; 2002.
31. Hastie T, Tibshirani R, Friedman JH. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd ed. New York, NY: Springer; 2009.
32. Meltzer CC, Smith G, DeKosky SG, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression and Alzheimer's disease. Neuropsychopharmacology 1998;18:407-30.
33. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 1979;135:216-23. (Pubitemid 9244805)
34. Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230:1273-6. (Pubitemid 16194533)
35. Bondareff W, Mountjoy CQ, Roth M. Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1981;1:783-4.
36. Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Tomlinson BE. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) 1981;282:93-4. (Pubitemid 11138339)
37. Elrod R, Peskind ER, DiGiacomo L, Brodkin KI, Veith RC, Raskind MA. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997;154:25-30. (Pubitemid 27020188)
38. Friedman JI, Adler DN, David KL. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry 1999;46:1243-52. (Pubitemid 30114441)
39. Winkeler A, Waerzeggers Y, Klose A, Monfared P, Thomas AV, Schubert M, et al. Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008;35(Suppl 1):S107-13.
40. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-6. (Pubitemid 36246085)
41. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, et al., The Parkinson Study Group. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992; 42:2111-7.